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Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular,
Not Plasma Membrane, Receptor Signaling
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Activating mutations in c-KIT are associated with gastrointestinal stromal tumors, mastocytosis, and acute
myeloid leukemia. In attempting to establish a murine model of human KITD816V (hKITD816V)-mediated
leukemia, we uncovered an unexpected relationship between cellular transformation and intracellular traf-
ficking. We found that transport of hKITD816V protein was blocked at the endoplasmic reticulum in a
species-specific fashion. We exploited these species-specific trafficking differences and a set of localization
domain-tagged KIT mutants to explore the relationship between subcellular localization of mutant KIT and
cellular transformation. The protein products of fully transforming KIT mutants localized to the Golgi
apparatus and to a lesser extent the plasma membrane. Domain-tagged KITD816V targeted to the Golgi
apparatus remained constitutively active and transforming. Chemical inhibition of intracellular transport
demonstrated that Golgi localization is sufficient, but plasma membrane localization is dispensable, for
downstream signaling mediated by KIT mutation. When expressed in murine bone marrow, endoplasmic
reticulum-localized hKITD816V failed to induce disease in mice, while expression of either Golgi-localized
HyKITD816V or cytosol-localized, ectodomain-deleted KITD816V uniformly caused fatal myeloproliferative dis-
eases. Taken together, these data demonstrate that intracellular, non-plasma membrane receptor signaling is
sufficient to drive neoplasia caused by mutant c-KIT and provide the first animal model of myelomonocytic
neoplasia initiated by human KITD816V.
The c-Kit gene is the mammalian homolog of the Hardy-
Zuckerman 4 feline sarcoma virus-transforming sequence (5),
maps to the murine white spotted (W) locus (12), and encodes
a type III receptor tyrosine kinase (RTK) (26, 31) sharing
strong sequence similarity to other type III RTK members
FLT3, FMS, and platelet-derived growth factor receptor (32).
The KIT receptor is expressed in hematopoietic stem cells,
mast cells, neural crest-derived melanocytes, and germ cells.
Immunoprecipitation studies of Kit expression demonstrated
two protein products, 160 kDa and 140 kDa, detectable in
Kit-expressing cells due to different posttranslational glycosyl-
ation (32). Binding to KIT ligand (stem cell factor [SCF]) leads
to receptor dimerization, activation of the intrinsic receptor
kinase, and initiation of a spectrum of downstream signaling
cascades responsible for various cellular responses, such as
proliferation, migration, and survival (7).
Gain-of-function mutations in c-KIT, causing constitutive,
ligand-independent activation of the receptor, were first iden-
tified in neoplastic mast cell lines of human, mouse, and rat
origins (11, 36, 37). Activating mutations in the human c-KIT
gene (KIT) occur in association with systemic mastocytosis
(24), gastrointestinal stromal tumors (33), germ cell tumors
(29), and acute myeloid leukemia (AML) (1, 15). Among these
mutations, D816V is the most frequent mutation. The wild-
type KIT receptor is widely expressed in the blast cells of
AML. KIT mutations in unselected AML cases occur only in
2% of cases, but occur at a high frequency in certain AML
subtypes, i.e., in about 48% of core binding factor leukemias
(2, 3, 38). In erythroleukemia developed in spi-1/PU.1 trans-
genic mice, acquired Kit mutations occur in 86% of tumors
(19). The KITD816V mutation is predicted to cause ligand-in-
dependent receptor activation by disrupting the structure of
the tyrosine kinase domain activation loop (10). Expression of
human KITD816V (hKITD816V) has been reported to transform
Myb-immortalized murine cells (10), but an animal model us-
ing primary hematopoietic cells expressing the human
KITD816V mutation has not been reported. Expression of the
homologous murine Kit mutation, encoding an identical aspar-
tic acid-to-valine substitution (KitD814V), induces factor-inde-
pendent growth of hematopoietic cell lines (17), transforms
normal hematopoietic cells (18), and induces lymphoid malig-
nancies in mice (18). Studies on FLT3 internal tandem dupli-
cation (FLT3 ITD) demonstrate that FLT3 activation induces
significantly reduced surface expression and increased accumu-
lation of immature protein in subcellular compartments, sug-
gesting that constitutive phosphorylation of the FLT3 receptor
impairs its posttranslational processing and trafficking (34);
however, the mechanisms contributing to this phenomenon
remain to be elucidated. Furthermore, it is known that accu-
mulated, immature KIT protein and other RTK receptors (i.e.,
FLT3 ITD) can be phosphorylated (9, 34); however, it is un-
clear whether phosphorylation of those non-membrane-local-
ized receptors is also biologically active and contributes to
tumorigenesis in vivo.
We sought to develop a mouse model of hKITD816V-induced
disease as a platform to dissect the molecular mechanisms
underlying RTK contributions to myeloid leukemia develop-
ment. To our surprise, murine cells were repeatedly and inex-
* Corresponding author. Mailing address: Washington University
School of Medicine, Campus Box 8007, 660 South Euclid Avenue, St.
Louis, MO 63110. Phone: (314) 362-9350. Fax: (314) 362-9333. E-mail:
tomasson@wustl.edu.
 Published ahead of print on 23 October 2006.
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plicably resistant to transformation by hKITD816V. Noting that
murine and human KIT extracellular domains are not struc-
turally identical, we hypothesized that the human KIT extra-
cellular domain was inhibiting proper protein expression and
preventing transformation of murine cells. While the C-termi-
nal intracellular signaling domains of the murine Kit and hu-
man KIT proteins are 93% homologous at the amino acid
level, the extracellular domains of mouse Kit and human KIT
share only 74% homology and have significant functional struc-
tural differences. Specifically, the ligand binding domains of
the human KIT receptor lie in the second immunoglobulin
(Ig)-like domain, while the binding site of the murine ligand
lies in an adjacent but noncontiguous region (20) and, corre-
spondingly, the murine and human KIT receptors do not pos-
sess identical ligand binding capabilities. To facilitate mutant
KIT receptor expression and transformation, we engineered
novel chimeric receptors (HyKITWT and HyKITD816V) by fus-
ing the extracellular and transmembrane domains of the mu-
rine Kit in frame to the intracellular signaling domain of hu-
man KIT. We compared the transformation potential of the
murine, human, and hybrid mutants by expressing hKITD816V,
mKitD814V, and HyKITD816V in cell lines of both murine and
human origins. We examined the expression and subcellular
localization of the encoded proteins using Western blotting,
flow cytometry, endoglycosidase digestion, and immunofluo-
rescence microscopy. We examined the downstream signaling
pathways activated by these KIT mutants and tested their abil-
ity to induce leukemia in murine bone marrow transduction/
transplantation assays. The results of intracellular localization,
signaling, and transformation experiments all supported the
model that hKITD816V is trapped by an endoplasmic reticulum
(ER) checkpoint, specifically in murine cells, that can recog-
nize differences between homologous human and murine mu-
tant glycoproteins. The HyKITD816V receptor overcame this
checkpoint block and uniformly induced fatal myeloprolifera-
tive disease (MPD) in mice, demonstrating a unique and useful
model of KIT-induced myeloid disease. Furthermore, by arti-
ficially targeting KIT expression to the Golgi apparatus, KIT
D816V retained its constitutive activation and transformation
potential; treatment with chemical inhibitors of intracellular
transport suggested that Golgi compartment localization was
sufficient for downstream signaling pathway activation medi-
ated by KIT mutation. Taken together, these data provide
strong evidence that the signaling activated by intracellularly
localized KIT receptor plays an important role in mutant KIT-
mediated transformation and tumorigenesis.
MATERIALS AND METHODS
Plasmid DNA constructs. pRUFNeo plasmids containing the whole coding
sequence of wild-type human KIT cDNA and activating mutant (816 Asp3Val;
D816V) human KIT cDNA were generously provided by Leonie Ashman (Han-
son Centre for Cancer Research, Adelaide, Australia). Two steps were used to
introduce both wild-type and mutant human c-KIT cDNA from pRUFNeo into
retroviral vector MSCV-IRES-eGFP (MIG): first, a BamHI-BglII upstream frag-
ment was ligated to the BglII site of MIG, and after orientation confirmation, the
downstream BglII-BglII fragment was introduced to create whole coding region
of the human c-KIT gene. The resulting constructs were named MIG-hKITWT
and MIG-hKITD816V, respectively. To create MIG-mKitD814V, murine Kit cDNA
containing the D814V mutation (kind gift from M. Mizuki, Osaka University
Graduate School of Medicine, Japan) was subcloned into the EcoRI site of MIG.
To generate murine-human hybrid KIT cDNA, the extracellular region and
transmembrane region of murine c-Kit cDNA were fused in frame with the
intracellular region of human c-KIT cDNA containing either the wild type or
D816V mutant. The resulting constructs were named MIG-HyKITWT and MIG-
HyKITD816V, respectively.
In order to target KIT intracellular domain expression to the cell membrane,
a fusion sequence consisting of the N-terminal 20 amino acids of neuromodulin,
also called GAP-43, and the entire c-KIT intracellular domain (ICD) was gen-
erated in frame by PCR and three-way ligation. The neuromodulin fragment
(GAP-43), which contains a signal for posttranslational palmitoylation of cys-
teines 3 and 4 (41), was synthesized by Integrated DNA Technologies Inc.
(Coralville, IA) with a BglII restriction site added to its 5 end and a NcoI site
added to its 3 end. KIT ICD fragments were amplified from MIG-hKITWT and
MIG-hKITD816V plasmids, respectively, using the Expand high-fidelity PCR sys-
tem (Roche Applied Science, Mannheim, Germany) with the following primers:
forward primer with NcoI restriction site, 5-CGCCCATGGCTGACCTACAA
ATATTTACAGAAACCC; reverse primer with EcoRI restriction site, 5-GGA
GAATTCAGACATCGTCGTGCACAAG. The GAP-43 fragment and KIT ICD
fragment were digested with appropriate restriction enzymes and subcloned into
the MIG retroviral vector, and resulting constructs were named MIG-GAP-
KITWT and MIG-GAP-KITD816V, respectively.
In order to target expression of the KIT intracellular domain specifically to the
Golgi apparatus, an in-frame fusion of FIG (fused in glioblastoma), a gene
coding for a Golgi apparatus-associated protein (8), to KIT ICD was generated
in a similar way as described above. A FIG-ROS cDNA, a kind gift from A.
Charest (MIT Center for Cancer Research, Cambridge, MA), was used as the
template to amplify the FIG fragment using the following primers: forward
primer with BglII restriction site, 5-AGTAAGATCTATGTCGGCGGGCGGT
CCATG; reverse primer with NcoI restriction site, 5-CCGCCCATGGTTGTA
ATACTTTGATTTCCC. The KIT ICD fragment was amplified as described
above. Both the FIG fragment and KIT ICD fragment were digested with ap-
propriate restriction enzymes and subcloned into the MIG retroviral vector, and
resulting constructs were named MIG-FIG-KITWT and MIG-FIG-KITD816V, re-
spectively. Ninety percent of FIG sequence, including the two coiled-coil motifs
and the PDZ domain, are retained in the FIG-KIT fusion protein.
To express only the KIT intracellular domain, the KIT ICD fragment was
amplified from MIG-hKITWT and MIG-hKITD816V plasmids, respectively. A BglII
restriction site and start codon ATG were added to the forward primer, 5-CG
CAGATCTATGCTGACCTACAAATATTTACAGA AACCC. 3 primer se-
quence was as described above. The PCR product was digested with BglII and
EcoRI and subcloned into the MIG retroviral vector. The constructs were named
MIG-ICD-KITWT and MIG-ICD-KITD816V, respectively.
The sequences of all constructs used in this study were verified by restriction
mapping and direct sequencing. All plasmids were prepared by double cesium-
banding purification.
Cell Culture. 293T cells, NIH 3T3 cells, and A375 cells were grown in Dul-
becco’s modified Eagle’s medium (Cambrex Bio Science Walkersville Inc., Walk-
ersville, MD) containing 10% fetal calf serum (FCS; HyClone, Logan UT) and
1 penicillin-streptomycin (Pen/Strep) in a humidified incubator at 37°C, 5%
CO2. Cytokine-dependent Ba/F3 murine hematopoietic cells and TF-1 human
hematopoietic cells were maintained in RPMI 1640 (Cambrex Bio Science Walk-
ersville Inc., Walkersville, MD) supplemented with 10% FCS, 1 Pen/Strep, and
1 ng/ml of either recombinant mouse interleukin-3 (rmIL-3; R&D Systems Inc.,
Minneapolis, MN) or rhIL3 (STEMCELL Technologies Inc., Vancouver, British
Columbia, Canada), respectively. K562 cells were grown in RPMI containing
10% FCS and 1 Pen/Strep. Primary murine bone marrow mononuclear cells
were plated in transplant medium consisting of RPMI 1640, 20% FCS, and 1
Pen/Strep with 10 ng/ml SCF, 6 ng/ml IL-3, 50 ng/ml Flt-3 (R&D Systems Inc.),
and 10 ng/ml thrombopoietin (PeproTech, Rocky Hill, NJ).
Retroviral production. Ecotropic retrovirus used to transduce murine cells was
generated by transient transfection of 293T cells as described previously (13).
Amphotropic retrovirus used to transduce human cells was generated by tran-
sient cotransfection of 293T cells with retroviral construct and packaging plas-
mids pMD.G and pMD.Gagpol. Viral supernatant was harvested 48 h posttrans-
fection, and the titer of the infectious virus was determined by flow cytometry
using NIH 3T3 cells infected with serial dilutions of virus in the presence of 10
g/ml of Polybrene (American Bioanalytical, Natick, MA).
Cell growth and proliferation assays. Murine cell line Ba/F3 cells or human
cell line TF-1 cells transduced with retroviruses were sorted by MoFlo (DAKO/
Cytomation) based on equivalent green fluorescent protein (GFP) expression
levels. Sorted cells were recovered with the appropriate growth medium as
described above and washed with RPMI 1640 thrice to remove growth factor
(IL-3) and resuspended with RPMI 1640 containing 10% FCS and 1 Pen/Strep.
Cells were plated into either 12-well plates or 96-well plates in the absence of
IL-3. Viable cells were counted daily by staining with trypan blue or evaluated by
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thiazolyl blue tetrazolium bromide (MTT) assay using the CellTiter 96 Aqueous
One Solution cell proliferation assay kit (Promega, Madison, WI).
Immunofluorescence staining. Cells growing on glass coverslips were trans-
fected with c-Kit MIG expression plasmids using SuperFect reagent (QIAGEN,
Valencia, CA) and fixed with 3.7% formaldehyde (Sigma-Aldrich, St. Louis,
MO) in phosphate-buffered saline (PBS) for 15 min at room temperature. After
three washes with PBS for 5 min each, cells were incubated with primary anti-
body with gentle agitation at room temperature for 1 h. Primary antibodies were
visualized by subsequent staining with secondary antibodies conjugated to either
Alexa Fluor 350, Alexa Fluor 594, or Alexa Fluor 633 (Molecular Probes Inc.,
Eugene, OR). Goat anti-c-Kit antibody (clone C-14; Santa Cruz Biotechnology,
Santa Cruz, CA) was used for detection of c-Kit protein. Golgi complex and
endoplasmic reticulum were stained with rabbit anti-GPP130 antibody (Covance
Research Products, Berkeley, CA) or rabbit anti-calnexin antibody (Sigma-Aldrich,
St. Louis MO), respectively. All antibodies were diluted in PBS containing 1
mg/ml bovine serum albumin, 0.2% Triton X-100, and 5% FCS. Images were
taken with a Zeiss LSM510 laser-scanning confocal microscope.
Semiquantitative RT-PCR. Total RNA was isolated from transduced and
sorted Ba/F3 cells using TRIzol reagent (Invitrogen, Carlsbad, CA). Reverse
transcription (RT) was performed with Superscript III (Invitrogen). PCR cycles
(18, 22, 26, and 30 cycles) were performed using the following primers: glycer-
aldehyde-3-phosphate dehydrogenase forward, 5-TGCAGTGGCAAAGTGGA
GATT, and reverse, 5-TTGAAGTCGCAGGAGACAACCT; c-Kit forward
primer, 5-GGCAGCCAGAAATATCCTCCTTAC, and reverse primer, 5-CA
CGGGCTTCTGTCGGTTGG.
Immunoblotting and immunoprecipitation. Cells were transduced with the
KIT allele and sorted based on equivalent GFP expression levels. Cells were
lysed in an appropriate amount of RIPA lysis buffer (50 mM Tris-HCl, pH 7.4,
150 mM sodium chloride, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA)
supplemented with 1 mM Na3VO4, 25 mM NaF, 1 mM phenylmethylsulfonyl
fluoride, and 1 Complete protease inhibitor cocktail (Roche, Indianapolis, IN).
Lysates were incubated for 15 min on ice and then cleared by centrifugation at
14,000  g for 15 min at 4°C. Freshly prepared lysates were used for all immu-
noprecipitations. Immunoprecipitations were performed by incubating 500 to
1,000 g total cell lysate on a rocker at 4°C for 2 h with polyclonal goat anti-c-Kit
antibody (C-14). Immunoprecipitates were collected with protein G-Sepharose
(Amersham-Pharmacia Biotech, Piscataway, NJ). Immunoprecipitates were
washed three times with lysis buffer and boiled for 5 min in sodium dodecyl
sulfate (SDS) sample buffer. Immunoblotting was performed following a stan-
dard protocol. Briefly, samples were separated by SDS-polyacrylamide gel elec-
trophoresis (SDS-PAGE) and transferred electrophoretically to nitrocellulose
membrane (Schleicher & Schuell BioScience, Keene, NH). Blot was blocked
with 5% dry milk in Tris-buffered saline-Tween 20 buffer and then incubated
overnight at 4°C with one of the following antibodies: goat anti-c-kit (C-14),
rabbit anti-phospho-c-kit (Tyr719; Cell Signaling Technology, Beverly, MA),
mouse anti-Akt and mouse anti-phospho-Akt, rabbit anti-p44/42 mitogen-acti-
vated protein kinase (MAPK) and rabbit anti-phospho-p44/42 MAPK (Cell
Signaling), rabbit anti-Stat3 and rabbit anti-phospho-Stat3 (Cell Signaling), rab-
bit anti-Stat5 and rabbit anti-phospho-Stat5 (Cell Signaling), rabbit anti-phos-
pho-(Tyr) p85 phosphatidyl inositol 3-kinase (PI3K) binding motif antibody (Cell
Signaling), and mouse anti--actin (Sigma, St. Louis, MO). Blots were incubated
with horeseradish peroxidase-conjugated secondary antibodies (Amersham Bio-
sciences Corp., Piscataway, NJ) and visualized by enhanced chemiluminescence
(Pierce Biotechnology, Rockford, IL).
Glycosidase treatment. Whole-cell lysates were treated with either peptide
N-glycosidase (PNGase F) or endo--N-acetylglucosaminidase H (Endo H)
(both from New England Biolabs, Ipswich, MA) for at least 2 h at 37°C per the
manufacturer’s instructions. The reactions were terminated with SDS-PAGE
sample buffer, and the reaction product was analyzed by immunoblotting as
described above.
Murine bone marrow transplantation. BALB/c female mice (6 to 8 weeks of
age) were purchased from Taconic Farms and maintained in an accredited
animal facility according to proper institutional guidelines. Retroviral transduc-
tion and transplantation of bone marrow cells were carried out as described
previously (35). Briefly, bone marrow mononuclear cells were isolated from the
femurs and tibias of donor mice pretreated with a single dose 5-fluorouracil (150
mg/kg of body weight) for 2 days. After 48 h of culture in transplant medium,
bone marrow cells were transduced by two rounds of spin-infection with equiv-
alent titer of retroviral stocks. Syngeneic recipient mice irradiated with 900 cGy
were transplanted intravenously with 1  106 unfractionated transduced bone
marrow cells. Samples were collected from moribund mice as described previ-
ously (13). Kaplan-Meier plots were generated on groups of mice on the basis of
cumulative survival after transplantation using STATVIEW software (SAS In-
stitute, Cary, NC). Cell morphology was performed on slides prepared from
peripheral blood (PB), bone marrow (BM), and spleen (SP) cells from sick mice
by May-Gru¨nwald/Giemsa staining and imaged as described elsewhere (25).
Flow cytometry. Flow cytometry was performed as described previously (13).
The antibodies used to detect the murine antigens were Gr-1, CD11b, CD117
(c-Kit), Sca-1, B220, CD43, IgM, CD3, CD4, CD8, and Ter-119. All antibodies
were purchased from BD PharMingen (San Jose, CA). Analysis was performed
on 7-aminoactinomycin D-negative cells by using FLOWJO software (Tree Star,
San Carlos, CA). Quadrants were set on the basis of isotype control antibodies
conjugated to phycoerythrin or peridinin chlorophyll a protein.
RESULTS
Human but not murine cells are rapidly transformed by
expression of human KITD816V. The KITD816V mutation is the
FIG. 1. Schematic diagram of KIT allele constructs and analysis of
protein expression in 293T cells. (A) Schematic diagram of wild-type
and mutant KIT constructs. Retroviral constructs were generated by
subcloning wild-type human KIT (hKITWT) cDNA and human KIT
cDNA containing a point mutation encoding an aspartic acid3valine
substitution at position 816 in the cytoplasmic activation loop of KIT
(hKITD816V) into the MSCV-IRES-GFP retroviral vector (MIG). Mu-
rine-human hybrid KIT alleles (HyKITWT and HyKITD816V) were gen-
erated by fusing in frame the extracellular/transmembrane domains of
murine Kit to the cytoplasmic domains of human KIT. The murine Kit
cDNA containing a mutation encoding the identical amino acid sub-
stitution at the identical conserved activation loop aspartic acid residue
(mKitD814V) was used as a control. Human sequences are indicated by
shaded boxes, and the murine sequence is indicated by open boxes.
The plus symbol indicates mutation in the cytoplasmic domain. (B) All
KIT allele constructs express transgene protein appropriately in human
293T cells. Whole-cell protein lysates from transient-transfected hu-
man 293T cells were analyzed by immunoblotting with antibody to
c-Kit recognizing intracellular domain of both human c-KIT and mu-
rine c-Kit proteins. Faster migration of mutant proteins was confirmed
in subsequent experiments (described in the text) to be due to differ-
ential glycosylation patterns. CG, complex glycosylation form; HM,
high-mannose (immature) form.
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FIG. 2. Cellular transformation by mutant hKITD816V is blocked in murine cells by posttranscriptional inhibition of protein expression and is restored by
murine extracellular/transmembrane sequences. (A) Transformation of murine Ba/F3 cells to cytokine-independent growth byKIT alleles. Ba/F3 cells expressing
different KIT alleles were starved of IL-3, and viable cells were counted daily by trypan blue exclusion. Cells expressing HyKITD816V and mKitD814V grew rapidly
following IL-3 withdrawal, but hKITD816V-expressing cells failed to grow after 1 week. After an additional week in culture, a subpopulation of hKITD816V-
expressing cells grew in the absence of IL-3 (not shown). Mock-infected, vector-alone, andHyKITWT control cell populations did not grow in the absence of IL-3
(same growth pattern ashKITWT) (data not shown). (B) Transformation of human TF-1 cells to cytokine-independent growth byKIT alleles. TF-1 cells expressing
different KIT alleles were starved of IL-3, and viable cells were counted daily. Human cells expressing hKITD816V (as well as HyKITD816V and mKitD814V) grew
in the absence of IL-3 without prolonged selection. (C) Expression and autophosphorylation of KIT receptor proteins in murine Ba/F3 cells. Total cell lysates
were prepared from Ba/F3 cells expressing different KIT alleles, immunoprecipitated with anti-c-Kit antibody, and blotted with either anti-Kit antibody or with
phospho-specific anti-Kit antibody. Expression of hKITD816V protein was significantly inhibited compared to HyKITD816V and mKitD814V proteins. CG, complex
glycosylated form; HM, high-mannose (immature) form. (D) Semiquantitative RT-PCR demonstrated equivalent expression of all KIT receptor alleles in Ba/F3
cells at the RNA level. Total RNA was isolated from transduced and sorted GFP-positive Ba/F3 cells from each construct, and an equal amount of total RNA
was used as template in RT-PCR with oligo(dT) primers for cDNA synthesis and gene-specific primers as indicated. PCR was carried out with 18, 22, 26, and
30 amplification cycles for linear range determination. Data from 22 and 26 cycles of PCR are shown here. Lanes 1 to 5, cDNA from different KIT alleles as
indicated; lane 6, positive control using MIG-hKITWT plasmid, 20 ng per reaction mixture; lanes 7 and 8, no RT control of RNA samples from hKITWT- and
hKITD816V-transduced Ba/F3 cells, respectively; lane 9, no-template water control. (E) Expression and autophosphorylation of KIT receptor proteins in human
TF-1 cells. Immunoprecipitation and immunoblotting were carried out as for panel C. In human cells, expression of mutant KIT receptor proteins, including
hKITD816V, achieved equivalent levels of protein expression.
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most common gain-of-function c-KIT mutation associated with
human diseases and is predicted to cause ligand-independent
receptor activation (24, 29, 33, 38). To test its transforming
potential in vitro and in vivo, we generated retroviral con-
structs expressing mutant KIT D816V (hKITD816V) along with
the homologous murine mutant Kit D814V (mKitD814V) (Fig.
1A) and validated their expression in transfected human 293T
cells by Western blotting (Fig. 1B). We assessed the ability of
these KIT alleles to transform murine IL-3-dependent Ba/F3
cells to growth factor independence. Surprisingly, homologous
mutant KIT alleles displayed significant differences in transfor-
mation potential (Fig. 2A). The fully murine mKitD814V caused
the most rapid outgrowth of cells in the absence of IL-3 but,
notably, we found that the hKITD816V failed to transform mu-
rine Ba/F3 cells in this short-term growth assay. This unex-
pected finding promoted us to wonder if hKITD816V could
transform cells from different cell lineages or origins, and we
repeated the experiments by expressing hKITD816V in both
murine 32D myeloid leukemia cells and human TF-1 erythroid
leukemia cells. In agreement with Ba/F3 data, hKITD816V could
not transform murine 32D cells (data not shown). In contrast
to the poor transformation potential of hKITD816V in murine
cells, hKITD816V could rapidly transform human TF-1 cells to
cytokine independence (Fig. 2B). We examined RNA expres-
sion of hKITD816V in these cells and found equivalent transcript
levels (Fig. 2D), but levels of the hKITD816V protein were
specifically reduced in murine Ba/F3 cells (Fig. 2C) in com-
parison to human cells (Fig. 1B and 2E). Reduced protein
expression of hKITD816V was also observed in murine 3T3 and
32D cells (data not shown), but robust hKITD816V expression
was observed in all human cell lines tested, including 293T,
TF-1, and K562 (Fig. 1B and 2E and data not shown). These
data suggest that levels of activated hKITD816V protein are
affected posttranslationally in murine cells and, associated with
low mutant protein levels, hKITD816V alone was unable to ef-
ficiently transform murine cells.
The extracellular domains of murine Kit and human KIT
share less homology than the intracellular signaling domains
and do not bind each others’ ligand with equal affinity (21). We
considered, first, the possibility that extracellular/transmem-
brane domains of hKITD816V might inhibit its transformation
potential in murine cells. To test this possibility, we generated
two “hybrid KIT” alleles containing the murine Kit extracellu-
lar and transmembrane domains fused in-frame to the intra-
cellular domain of wild-type human KIT (HyKITWT) or the
D816V mutant (HyKITD816V) (Fig. 1A). Proliferation assays
demonstrated that replacement of the human extracellular and
transmembrane domains of hKITD816V with homologous mu-
rine sequences (HyKITD816V) rescued the transforming ability
in murine cells (Fig. 2A). Second, we examined the possibility
that the KIT ligand (SCF) might be still required for transfor-
mation by hKITD816V. However, proliferation assays using
FIG. 3. KITD816V receptors induce ligand-independent growth. (A) Murine ligand stimulates growth of TF-1 cells expressing hKITWT and
HyKITWT. Parental and transduced TF-1 cells were washed three times with RPMI 1640 to remove IL-3 and restimulated with 100 ng/ml rmSCF.
At 48 h after restimulation, cell proliferation was measured by MTT assay. (B) Human ligand only stimulates growth of TF-1 cells expressing
hKITWT but not HyKITWT. (C) Cells expressing HyKITD816V are insensitive to Kit ligand. Transduced Ba/F3 cells were washed three times to remove
IL-3 and restimulated with rmSCF with various dosages. Cell proliferation was measured by MTT assay. Cells expressing HyKITWT responded to
rmSCF in a dose-dependent manner, while cells expressing HyKITD816V grew in a dose-independent manner. (D) Cells expressing hKITD816V are
insensitive to KIT ligand. Ba/F3 cells expressing hKITD816V were starved of IL-3 for 1 week, and then prestarved hKITD816V cells were used for MTT
assay as described above.
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either human KIT ligand or murine Kit ligand demonstrated
that both hKITD816V and HyKITD816V induced cell growth in a
cytokine-independent manner (Fig. 3). These results are con-
sistent with previously reported data (28) and confirm that the
D816V mutation causes truly ligand-independent activation of
the KIT receptor. Taken together, our data suggest that effi-
cient expression and the transforming potential of the
KITD816V protein depends upon species context and that the
human extracellular domain of KITD816V impairs transformation
in murine cells.
Transformation potential of human KITD816V receptor as-
sociated with subcellular localization. We sought to under-
stand the mechanism by which the extracellular/transmem-
brane domains of hKITD816V inhibited its transformation
potential in murine cells. Our data suggested that levels of
activated hKITD816V protein were affected posttranslationally
by species context and that replacement of the human extra-
cellular and transmembrane domains of hKITD816V with ho-
mologous murine sequences (i.e., HyKITD816V) rescued the
impaired expression and transforming ability in murine cells.
The half-life of activated mutants of murine Kit receptor is
significantly shorter than the half-life of wild-type receptor, yet
rapidly degraded murine receptors retain their transforming
potential (28), and so we hypothesized that the subcellular
localization of mutant KIT receptors might explain our find-
ings. We first used flow cytometry to examine the expression of
murine and human KIT proteins at the cell surface (Fig. 4A).
The wild-type KIT receptors (both human and hybrid), as
expected, were expressed at high levels on the cell surface of
murine Ba/F3 cells. The constitutively active mKitD814V and
HyKITD816V receptors were detectable on the cell surface,
albeit at reduced levels compared to wild-type receptor (Fig.
4A). In contrast, the hKITD816V receptor was not significantly
expressed on the surface of Ba/F3 cells (Fig. 4A). In human
TF-1 cells, this pattern was repeated, except that hKITD816V
was expressed on the cell surface. Furthermore, the cell surface
expression pattern of cytokine-independent HyKITD816V- and
mKitD814V-transduced Ba/F3 cells did not change after IL-3
FIG. 4. The transforming potential of different KIT alleles is associated with distinct patterns of subcellular KIT receptor localization.
(A) Analysis of KIT receptor expression on the cell surface by flow cytometry. Wild-type receptors are expressed at a high level on murine Ba/F3
cells (upper panels) and human TF-1 cells (lower panels). The activated hKITD816V receptor was not present on the surface of Ba/F3 cells but was
present at low levels in TF-1 cells. HyKITD816V and mKitD814V were present at low/intermediate levels on the surface of both Ba/F3 and TF-1 cells.
Shaded curves are isotype control staining. Dashed curves are mocked transduction control staining and represent endogenous KIT expression
level. (B) Trafficking of human c-KIT D816V protein is blocked in the ER system in murine cells. Transiently transfected murine NIH 3T3 cells
and human A375 cells were costained with anti-c-Kit antibody and anti-calnexin (ER marker) antibody, and all images were taken with a Zeiss
LSM510 laser-scanning confocal microscope. Wild-type KIT was localized to the Golgi apparatus and cell surface of both human and murine cells.
The hKITD816V mutant receptor was restricted to the ER of murine cells but was able to traffic to the Golgi apparatus in human cells. HyKITD816V
was present prominently in the Golgi complex and also at the plasma membrane in both murine and human cells. Immunofluorescent staining for
mocked controls and vector-only controls was appropriately negative for KIT staining (not shown); the immunofluorescent staining pattern
for HyKITWT-transfected cells was very similar to hKITWT-transfected cells both in murine cells and human cells (not shown); the staining pattern
for mKitD814V-transfected cells was very similar to HyKITD816V in both murine cells and human cells (not shown). Arrows, cell plasma membrane
staining. (C) Murine NIH 3T3 cells and human A375 cells expressing different KIT alleles were costained with anti-c-Kit and anti-GPP130 (Golgi
marker) antibodies. Again, hKITWT was present both at the plasma membrane and the Golgi apparatus. In murine cells, hKITD816V protein was
localized in an ER-specific pattern but colocalized to the Golgi apparatus in human cells. Triangles, Golgi complex staining. (D) Whole-cell lysates
prepared from transfected 293T cells were treated with PNGase F and analyzed by immunoblotting following standard protocols. Complete
digestion demonstrated that KIT alleles used in this study expressed protein products of identical size. CG, complex glycosylated form; HM,
high-mannose (immature) form; DG, deglycosylated protein. (E) Whole protein lysates from transfected 293T cells were treated with Endo H.
Wild-type KIT receptors are protected from Endo H digestion by mature glycosylation. Mutant KITD816V (both human and hybrid) and mKitD814V
receptors are sensitive to Endo H digestion, indicating an immature, high-mannose glycosylation pattern. These data are consistent with a failure
of mutant KIT receptors to traffic normally through the trans-Golgi network.
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starvation, suggesting that those cells lacking KIT surface ex-
pression could proliferate with constitutively active KIT signal-
ing from an intracellular compartment (data not shown). We
initially hypothesized that mutant KIT might be stabilized in
TF-1 cells by the formation of higher-order structures, e.g.,
heterodimers with endogenous wild-type KIT or erythropoie-
tin (Epo) receptor signaling complexes (39), but we examined
a series of cell lines for their ability to express hKITD816V on
their cell surface and found that nonhematopoietic human
cells (without endogenous KIT or EpoR expression) allowed
surface expression of hKITD816V, while none of the murine
cells tested were able to express hKITD816V on their surface
(Table 1). Therefore, the ability of cells to express hKITD816V
at the plasma membrane was not associated with cell type but
was consistently associated with the species of origin of the
cells in which the mutant KIT was expressed.
We further examined the subcellular localization of KIT
receptors directly in murine and human cells using immuno-
fluorescence costaining and confocal microscopy. Using anti-
bodies to costain the KIT receptor and Golgi apparatus or ER,
cells expressing wild-type receptors demonstrated a stain pat-
tern consistent with both Golgi and cell surface localization
(Fig. 4B and C and data not shown). In sharp contrast, the
staining of murine cells expressing hKITD816V demonstrated an
exclusively ER localization pattern. There was a significant
difference in the staining pattern in human cells expressing
KITD816V, with predominantly Golgi apparatus staining, with a
small amount of signal also detected at the cell surface and in
punctate cytoplasmic vesicles (Fig. 4B and C). Importantly,
HyKITD816V and mKITD814V were localized both to Golgi and
plasma membrane compartments in both human and murine
cells (Fig. 4B and C and data not shown). Consistent with the
data obtained from flow cytometry, activated KIT receptors
not blocked by the ER (i.e., hKITD816V in human cells,
HyKITD816V, and mKitD814V) were present abundantly in the
Golgi apparatus but at decreased levels at the plasma mem-
brane. Therefore, replacement of the human extracellular and
transmembrane domains of human KIT with the homologous
murine sequences allowed trafficking of receptors through the
ER to the Golgi apparatus and restored the ability of KITD816V
to transform murine cells.
Progress of glycoproteins through the cis- and trans-Golgi
complex is associated with distinct stages of glycosylation. Dif-
ferent KIT receptor proteins demonstrated similar electro-
phoretic mobilities following complete digestion of oligosac-
charide groups by PNGase F (Fig. 4D). Complex (i.e., mature)
oligosaccharide modification can be distinguished from imma-
ture high-mannose-type oligosaccharides by digestion with
Endo H, which selectively cleaves high-mannose sugars. The
wild-type KIT proteins, including hKITWT and HyKITWT,
were resistant to Endo H cleavage, while the activated alleles,
including hKITD816V, HyKITD816V, and mKitD814V, were sen-
sitive to Endo H digestion (Fig. 4E), indicating that protein
maturation of KIT mutants was impaired. Taken together,
these data suggest that while wild-type KIT receptors traffic
normally through the trans-Golgi complex to undergo complex
glycosylation, constitutively active KIT proteins are impaired
from trafficking through the trans-Golgi complex and do not
undergo terminal glycosylation. In murine cells expressing
hKITD816V, however, the disruption of receptor transport oc-
curred earlier, in the ER, and was more complete, resulting in
a total lack of surface expression and a failure to achieve
cellular transformation.
Mutant KIT receptor retained in the ER fails to induce
leukemia in mice. To characterize the ability of murine, hu-
man, and hybrid KIT receptors to mediate malignant transfor-
mation and disease in vivo, we used ecotropic murine stem cell
virus (MSCV) retrovirus to express KIT alleles (Fig. 1) in
primary murine bone marrow cells and monitored transplanted
recipient mice for the development of disease. Consistent with
our data demonstrating that hKITD816V was trapped in the ER
and unable to transform murine cells in culture, we found mice
transplanted with hKITD816V did not develop disease (Fig. 5A;
Table 2). In sharp contrast, 100% of mice transplanted with
HyKITD816V developed a rapidly fatal MPD with massive ex-
pansion of maturing myeloid cells and infiltration of peripheral
blood, bone marrow, spleen, liver, and lungs evidenced by
leukocytosis, splenomegaly, and increased GFP Mac-1 cells
in peripheral blood, bone marrow, and spleen (Fig. 5A, B, and
D, Table 2, and data not shown). All mice transplanted with
the mKITD814V (100%) succumbed to a rapidly fatal leukemia
TABLE 1. c-Kit surface expression in different cell linesa
Allele
Surface expression (% of cells)
Murine Human
3T3 Ba/F3 293T K562 TF-1
MIG 0.3 0.2 0.3 0.2 19.3
hKITWT 82.5 94.9 97.8 86.0 73.2
hKITD816V 3.6 5.9 79.0 49.2 50.6
HyKITWT 99.4 87.1 98.6 93.5 79.6
HyKITD816V 30.4 35.5 66.8 49.3 55.0
mKitD814V 49.8 36.4 87.8 57.8 61.3
a A variety of murine and human cell lines were transduced with KIT alleles,
and KIT receptor surface expression was assessed by flow cytometry.
FIG. 4—Continued.
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as well, characterized by leukocytosis, splenomegaly, and neu-
ral system infiltration (Table 2 and data not shown). The leu-
kemia phenotype of mice expressing mKitD814V morphologi-
cally and immunophenotypically resembled human pre-B-cell
acute lymphocytic leukemia (Fig. 5A, C, and E and Table 2).
Notably, although the vast majority of bone marrow and spleen
cells from HyKITD816V and mKitD814V recipient mice were
GFP positive (90%), only about one-third of those GFP
cells had detectable Kit surface expression when analyzed by
flow cytometry (Fig. 5B and C).
Plasma membrane localization of the KIT receptor is dis-
pensable for leukemia induction. To better characterize the
contribution of localized pools of KIT protein to cellular trans-
formation, we constructed a series of localization domain-
tagged KIT mutants by fusing the ICD of KIT in frame to the
N-terminal 20-amino-acid palmitoylation domain of GAP-43
(GAP-KIT, targeting to the cell membrane) or to the N-ter-
minal Golgi localization domain of FIG (FIG-KIT, targeting to
the Golgi apparatus) (Fig. 6A). All domain-tagged KIT mu-
tants and the ICD alone (ICD-KIT) expressed proteins of
expected sizes in human 293T cells (Fig. 6B), and probing with
anti-phospho-KIT antibodies demonstrated that KIT trunca-
tion and heterologous domain fusion by itself did not induce
receptor auto-activation. However, KIT proteins with the
D816V mutation were constitutively phosphorylated (Fig. 6B).
We confirmed successful targeting of localization domain-
tagged KIT proteins to specific cellular compartments by con-
focal microscopy. As anticipated, FIG-KITWT was localized to
the Golgi apparatus, GAP-KITWT was localized to the plasma
membrane, and ICD-KITWT, lacking a signal peptide and
transmembrane domain, was found diffusely in the cytoplasm
(Fig. 6C). Constitutive activation did not affect the Golgi lo-
calization pattern of FIG-KIT or the cytoplasmic localization
of ICD-KIT. However, GAP-KITD816V, unlike its wild-type
counterpart, was found localized to the Golgi apparatus (Fig.
6C). Therefore, trafficking of activated GAP-KITD816V to the
plasma membrane was abrogated independently of the extra-
cellular domain by an unknown mechanism.
We sought to determine the functional significance of KIT
proteins localized to specific cellular compartments by express-
ing localization domain-tagged KIT proteins in Ba/F3 cells and
in the bone marrow of mice by using retroviral transduction/
bone marrow transplantation. Localization domain-tagged
KIT proteins containing the wild-type ICD failed to transform
Ba/F3 cells to factor independence following IL-3 withdrawal
(data not shown). In contrast, Golgi-localized FIG-KITD816V
transformed Ba/F3 cells to IL-3 independence with similar
growth kinetics to HyKITD816V. GAP-KITD816V also allowed
factor-independent growth, albeit at a slower rate (Fig. 6D).
FIG. 5. KIT mutants associated with Golgi-localized KIT receptors
induce hematopoietic diseases in mice. (A) Kaplan-Meier survival
curves of mouse cohorts transplanted with bone marrow transduced
with various KIT alleles. Three independent transplantations were
performed for each construct. Mice transplanted with HyKITD816V-
transduced bone marrow mononuclear cells (BMMNC) succumbed to
a fatal MPD; mice transplanted with mKitD814V-transduced BMMNC
developed acute B-lymphocytic leukemia. Mice transplanted with
hKITD816V expressing BMMNC did not succumb to disease after 12
months of observation. (B and C) Immunophenotype analysis of he-
matopoietic cells from representative sick mice by flow cytometry.
(B) Spleen cells from HyKITD816V-induced MPD express predomi-
nantly myeloid markers Mac-1 and Gr-1. GFP-positive cells account
for 98% of splenocytes, but surface expression of KIT was only de-
tected on 33% of cells. Antibodies used cannot distinguish endogenous
Kit from transgenic KIT. (C) Spleen cells from mkitD814V-induced
disease express pro-B-cell markers B220 and CD43 and are IgM neg-
ative. Again, the vast majority of splenocytes (91%) were GFP positive,
but only 39% of cells coexpressed GFP and KIT. (D and E) Cell
morphology of PB, BM, and SP from representative leukemic mice.
(D) Cell morphology of PB, BM, and SP from HyKITD816V-induced
MPD mice shows infiltration with myeloid cells. (E) Cell morphology
of PB, BM, and SP from mKitD814V-induced B-cell leukemia shows
infiltration with lymphoid leukemic blasts. No histological abnormality
was detected in the hKITD816V-transplanted mice or wild-type control
mice (not shown).
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Surprisingly, cytosol-localized ICD-KITD816V also transformed
Ba/F3 cells to factor independence (Fig. 6D). We performed
retroviral transduction/bone marrow transplantation using
ICD-KIT and ICD-KITD816V. Mice transplanted with ICD-
KITD816V rapidly and uniformly succumbed to fatal MPD with
a median survival similar to that for mKitD814V disease mice
(Fig. 6E and F and Table 2), while ICD-KITWT mice survived
normally, demonstrating in vivo KIT-mediated transformation
is independent of the secretory pathway entirely. These data
demonstrate that Golgi localization is sufficient and plasma
membrane localization is dispensable for KITD816V-driven
transformation.
Intracellular trafficking modulates downstream signaling by
the KITD816V receptor. Transformation of cells by KIT activa-
tion is ultimately mediated by downstream signaling pathways
(22), and we sought to characterize the signaling pathways
activated by transforming versus nontransforming KIT alleles.
We used Western blotting with phospho-specific antibodies to
examine the activation status of downstream signaling path-
ways in Ba/F3 cells expressing the transforming HyKITD816V
and the nontransforming hKITD816V. We found Akt, Stat3, and
Stat5 signaling was activated by HyKITD816V, but these path-
ways were activated to a lesser extent, or not at all, by
hKITD816V (Fig. 7A). In contrast, we observed equivalent or
perhaps even increased levels of MAPK signaling, as measured
by phospho-ERK antibody, in cells expressing the ER-local-
ized hKITD816V (Fig. 7A). Using a high-affinity monoclonal
antibody directed toward the phosphorylated consensus bind-
ing sequence of the PI3K p85 subunit, we observed dramatic
increases in the abundance of proteins expressing this epitope
in all cells expressing activated KIT alleles, including
hKITD816V (Fig. 7A). Therefore, expression of the ER-local-
ized hKITD816V was sufficient to activate certain downstream
signaling pathways (e.g., MAPK-ERK, p85 binding epitope),
but activation of other pathways (e.g., Stat3, Stat5, and Akt)
required trafficking past the ER.
We sought to determine the relative contributions of the
Golgi apparatus and cell surface pools of mutant KIT receptor
to malignant transformation. We treated 3T3 cells expressing
the transformation-competent membrane/Golgi-localized
HyKITD816V or cytosol-localized ICD-KITD816V with monensin
or brefeldin A (BFA), compounds that disrupt Golgi structure
via different mechanisms, and assessed the impact of these
disruptions on the activation of downstream signaling path-
ways. Treatment with BFA, which causes fusion and retrograde
transport of resident proteins from the Golgi complex to the
ER (23), completely eliminated downstream Akt, MAPK,
and Stat3 signaling in HyKITD816V-expressing cells but not
ICD-KITD816V-expressing cells (Fig. 7B and C). In contrast,
monensin treatment, which preferentially affects the trans-
Golgi network and disrupts secretory vesicle transport to the
plasma membrane (27), had little effect on Akt, MAPK, and
Stat3 signaling by both HyKITD816V and ICD-KITD816V (Fig.
7D and E). Therefore, BFA treatment mimicked the phenom-
enon we noted with hKITD816V in murine cells, i.e., oncogenic
signaling was disrupted by mislocalization of mutant KIT to the
ER. In contrast, disruption of vesicular transport from the
trans-Golgi network to the cell surface by monensin did not
significantly affect signaling by mutant KIT. Taken together,
these data demonstrate that plasma membrane localization is
dispensable for intracellular signaling activation by mutant
KIT receptor.
DISCUSSION
Recent data have demonstrated that phosphorylation of the
FLT3 ITD results in aberrant intracellular receptor trafficking
(34). Here, we present the first data demonstrating the func-
tional consequences of aberrant RTK localization. Expression
of hKITD816V rapidly transformed human hematopoietic cells
to factor independence but was not sufficient to transform
murine Ba/F3 cells in short-term assays. Murine cells, but not
human cells, localized the hKITD816V protein exclusively to the
ER, while HyKITD816V and mKITD814V were transported
through the Golgi apparatus. In contrast to wild-type KIT
receptor, activated mKitD814V and HyKITD816V receptors were
expressed at low levels at the plasma membrane and were
predominantly immature glycosylated forms consistent with a
partial block of transport in the Golgi complex. We confirmed
that wild-type KIT receptor is a surface glycoprotein resistant
to Endo H cleavage, consistent with mature glycosylation ob-
tained through a complex series of modifications that occur in
the trans-Golgi system. In contrast, the human, murine, and
hybrid KIT mutant receptors were significantly sensitive to
Endo H digestion, demonstrating a failure to achieve a mature
glycosylation pattern consistent with the model that constitu-
tively activated KIT receptors do not traffic normally through
the trans-Golgi network. The failure of constitutively active
RTKs to traffic through the Golgi apparatus is not complete.
We observed two biochemically distinct pools of receptor: im-
mature (i.e., high-mannose) receptor and a smaller pool of
completely glycosylated receptor that coincides with detection
at the plasma membrane. Data from flow cytometry, immuno-
fluorescence, and endoglycosidase experiments were consis-
TABLE 2. Clinicopathological features of diseases induced by c-Kit mutations
Kit mutant n Median survival(days)
PB WBCa
(103/l)
Spleen wt
(mg)
Infiltration
Paralysis
Liver b Lung b
hKITD816V 15 NEDc 7.9  1.9 80  10   
HyKITD816V 15 68  22 386  235 1,070  185   2/15
mKitD814V 15 46  17 40  80 445  231   9/15
ICD-KITD816V 10 43  23 217  147 600  53   
a PB WBC, peripheral blood white blood count.
b Liver and lung infiltration levels were assessed by microscopic examination of formalin-fixed, hematoxylin and eosin-stained tissue sections.
c NED, no evidence of disease.
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tent and supported a model of KIT receptor trafficking depen-
dent upon phosphorylation as well as species context (Fig. 2, 4,
and 7). We used BFA and monensin to disrupt Golgi process-
ing at distinct points to characterize the functional significance
of these different KIT forms. Complete Golgi disruption with
BFA abolished downstream Akt, MAPK, and Stat3 signaling
by chemically localizing the receptor in the ER, effectively
mimicking the result we observed with ER-localized
hKITD816V. In contrast, monensin disruption of the trans-Golgi
network and vesicular transport to the plasma membrane had
minimal effect on the activation of leukemia-associated down-
stream signaling (Fig. 7). Furthermore, the D816V mutation
artificially targeted to the Golgi apparatus (FIG-KITD816V) and
even cytosolic form (ICD-KITD816V) were biologically active in
vitro and in vivo. These results suggest that the Golgi-localized
immature KIT form is necessary and sufficient to induce leu-
kemogenic signals. In contrast hKITD816V, trapped in the ER,
was unable to cause disease in mice. However, despite poor
surface expression, mKitD814V and HyKITD816V uniformly in-
duced fatal leukemias. The HyKIT oncogene that we describe
here will be useful for studying the mechanisms by which KIT
mutations contribute to the transformation of primary murine
cells, e.g., in core binding factor leukemias.
The extracellular/transmembrane domains of KIT were crit-
ical for subcellular localization and leukemogenesis, but it was
unclear why mKitD814V and HyKITD816V with identical extra-
cellular and transmembrane domains caused distinct pheno-
types (B-lymphoid versus MPD) when expressed in mice (Fig.
6). To assess differences between the murine and human in-
tracellular domains that might be functionally relevant, we
used a neural network program to predict sites of tyrosine
phosphorylation (6). Ten conserved tyrosines were identified
in the mKit cytoplasmic tail that were predicted phosphoryla-
tion targets on the basis of surrounding consensus sequences.
FIG. 6. Plasma membrane localization is dispensable for mutant KIT-induced neoplasia. (A) Schematic diagram of domain-tagged KIT allele
targeting constructs. The KIT receptor consists of an extracellular domain (ECD), a transmembrane domain (TM), and an intracellular domain
(ICD) which has two tyrosine kinase domains (TK). ICD-KIT only expresses the truncated intracellular portion of the KIT receptor; the GAP-KIT
fusion protein fuses the first 20 amino acids of GAP-43 in frame to the KIT ICD; the FIG-KIT fusion protein fuses the majority (90%) of FIG
in frame to the KIT ICD. CC, coiled-coil domain; PDZ, PDZ domain. (B) Western blot of total cell lysates from 293T cells expressing each
domain-tagged KIT allele targeting construct. Full-length hKITWT and hKITD816V were used as positive control. Molecular weights of mutant
domain-tagged KIT alleles were bigger than wild-type counterparts, probably due to posttranslational modification (i.e., phosphorylation), which
also altered the binding capacity to anti-total Kit antibody. All D816V alleles are highly phosphorylated. (C) Protein localization analysis by
immunofluorescent staining and confocal microscopy. NIH 3T3 cell transfection and immunofluorescent staining were performed as described for
Fig. 4, and all images were taken with a Zeiss LSM510 laser scanning confocal microscopy. Arrows indicate Golgi colocalization of KIT protein.
(D) Transformation potential of each targeting KIT allele. Murine Ba/F3 cells were transduced and sorted based on the same GFP expression level,
IL-3 was removed from growth medium, and viable cells were counted daily. Parental Ba/F3 cells, Ba/F3 cells transduced with vector alone, and
wild-type alleles could not grow in the absence of IL-3 (data not shown). (E) The intracellular portion alone of mutant KIT receptor is able to
induce MPD in mice. Phenotype was confirmed by histopathology, flow cytometry (data not shown), and cell morphology. (F) Cell morphology
of PB, BM, and SP from an ICD-KITD816V-induced MPD mouse indicates predominantly mature myeloid cells.
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A single amino acid substitution (D747G) in hKIT significantly
disrupted the consensus sequence for phosphorylation of ty-
rosine 749 (murine score, 0.713; human score, 0.199). As a
result, hKIT contains one less consensus tyrosine phosphory-
lation site than mKit (9 versus 10). Therefore, the different
leukemia phenotypes induced by mKitD814V and HyKITD816V
may be due to differential binding of an unidentified SH2
domain-containing signaling intermediate at tyrosine 749.
The Golgi apparatus is an important source of leukemo-
genic signals. Because ligand-mediated activation of cytokine
receptors occurs at the cell surface, it is generally assumed that
activation of canonical signaling pathways by mutant receptors
requires plasma membrane localization. However, increasing
evidence has suggested that cell surface binding of the receptor
may be dispensable for transformation. The simian sarcoma
virus gene product v-Sis induces autocrine activation of plate-
let-derived growth factor receptor (4, 14, 16, 40). The FIG-
ROS fusion protein is expressed as a result of a chromosome
6 microdeletion in a neuroblastoma cell line and involves ac-
tivation of the c-Ros RTK by receptor localization to the Golgi
apparatus, and this Golgi localization is sufficient and required
for cellular transformation mediated by FIG-ROS (8). Re-
cently, noncanonical activation of the Ras/MAPK pathway has
been found to occur at the endosome and the Golgi apparatus,
and that compartmentalized Ras signaling may modulate dis-
tinct functional outcomes (30). Here, we showed that mutant
KIT proteins were predominantly localized to the Golgi appa-
ratus and present only at low abundance on the cell surface.
We further targeted KIT expression specifically to the Golgi
compartment and found that FIG-KITD816V could transform
Ba/F3 cells to cytokine independence (Fig. 6D). We also per-
formed retroviral transduction/bone marrow transplantation
using other domain-tagged KIT constructs (GAP-KIT and
FIG-KIT). Preliminary data showed that both Golgi-localized
GAP-KITD816V and FIG-KITD816V could cause diseases in
mice (unpublished data). Both in vitro and in vivo data clearly
support that Golgi localization is sufficient for KITD816V-
driven transformation. We also used monensin and brefeldin A
to inhibit protein transport from the Golgi apparatus and ER,
respectively and, consistent with our transformation data,
found that Golgi localization, not plasma membrane localiza-
tion, was required to activate downstream signaling pathways.
We cannot exclude the possibility that important signals may
also be contributed by post-Golgi transport vesicles, but the
amount of KIT protein detected in these vesicles by immuno-
fluorescence was small. Taken together, these data demon-
strate that intracellular compartments, such as the Golgi ap-
paratus, are important contexts for oncogenic signaling events
previously thought to be exclusive to the plasma membrane.
The mechanisms by which oncogenic RTKs activate down-
stream signaling pathways such as Ras/MAPK and PI3K/Akt,
independent of the plasma membrane, remain to be deter-
mined.
Our results may be relevant to the treatment of human
cancers driven by mutant RTKs. Our data predict that RTK-
driven cancers may acquire resistance to extracellular domain-
targeted antibody therapies, such as Herceptin, by mechanisms
to downregulate or eliminate cell surface expression. Also, our
results suggest that the ER misfolded protein checkpoint may
represent a novel therapeutic target for patients expressing
activated RTK mutations. A subtle shift in KIT receptor traf-
ficking was sufficient to convert the hKITD816V gene product
from cancer initiator to an apparently harmless misfolded pro-
tein. Strong blockade of the secretory apparatus would likely
be highly toxic, but a therapeutic window might be identi-
FIG. 7. Subcellular localization of mutant KIT protein affects
downstream signal transduction. (A) Downstream signal transduction
pathways activated by various KIT alleles. Ba/F3 cells expressing var-
ious KIT alleles or vector alone were starved of IL-3 overnight, and
total cell lysates were analyzed by SDS-PAGE and blotted with phos-
pho-specific antibodies and total antibodies. ER-localized hKITD816V
strongly activates ERK and the PI3K consensus binding motif but does
not strongly activate Akt, Stat3, and Stat5. Golgi/plasma membrane-
localized HyKITD816V and mKitD814V activate Akt, Stat3, and Stat5
pathways. (B and C) Dissection of signaling pathways activated by
mutant KIT after inhibiting protein transport by BFA. NIH 3T3 cells
transduced with retroviral supernatant were treated with 5 g/ml BFA
for 20 h, a single-cell suspension was prepared for flow cytometry
analysis, and total cell lysates were prepared for signaling analysis
following a standard protocol described previously. (B) Flow cytometry
analysis of KIT surface expression in NIH 3T3 cells with or without
BFA treatment. BFA completely blocked KIT receptor transport to
the cell surface. Gray line, isotype control; dashed line, with BFA
treatment; solid line, no BFA. (C) Downstream Akt, Erk, and Stat3
signaling was completely abrogated in HyKITD816V-expressing cells but
not in ICD-KITD816V cells by Golgi disruption and retrograde trans-
port to the ER induced by BFA. (D and E) Mosensin had a minimal
effect on downstream signaling activation mediated by KIT mutants.
NIH 3T3 cells transduced with retroviral supernatant were treated
with 3 M monensin for 48 h, a single-cell suspension was prepared for
flow cytometry analysis, and total cell lysates were prepared for sig-
naling analysis following a standard protocol described previously.
(D) Flow cytometry analysis of KIT surface expression in NIH 3T3
cells with or without monensin treatment. Monensin significantly re-
duced KIT receptor expression by 96% at the cell surface. Gray line,
isotype control; long dashed line, with monensin treatment; solid line,
no monensin. (E) Monensin had little effect on downstream Akt, ERK,
and Stat3 signaling activated by mutant Kit receptors.
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fied; a partial chemical block might interfere specifically
with the processing and localization of pathogenic oncopro-
teins. Understanding the molecular mechanism by which
mutant KIT alleles activate disease-causing downstream sig-
naling pathways will allow us to identify and test novel
therapeutic strategies.
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